scholarly journals Prophylactic Efficacy of Scopolamine Butylbromide for FOLFIRINOX-induced Dysarthria

2018 ◽  
Vol 44 (9) ◽  
pp. 458-463
Author(s):  
Daisuke Kobayashi ◽  
Tatsuya Ohtsubo ◽  
Shoko Tsuji ◽  
Masaki Fujita ◽  
Shinji Sawada ◽  
...  
Keyword(s):  
Prophylactic Efficacy ◽  
Scopolamine Butylbromide

Maintenance acne therapy: prophylactic efficacy of fixed combination of adapalene and benzoyl peroxide

2020 ◽  
pp. 57-62
Author(s):  
L. S. Kruglova ◽  
N. V. Gryazeva
Keyword(s):  
Maintenance Therapy ◽  
Fixed Combination ◽  
Psychological Impact ◽  
Supportive Therapy ◽  
Prophylactic Efficacy ◽  
Severe Acne ◽  
Topical Retinoids ◽  
Acne Therapy ◽  
Group 2 ◽  
Treatment Observation

Acne is a chronic disease and even reliable therapies do not completely ensure absence of relapses. Acne relapses have a negative psychological impact on patients, as they feel unable to control the disease and achieve complete and long-lasting recovery. Supportive therapy is necessary to prolong the remission of acne achieved with initial successful treatment and to minimize the risk of relapse. According to the literature sources, the most justified as a maintenance therapy is the use of topical retinoids, which have been shown to be effective in the prevention of exacerbations of acne. In the present study 54 patients were involved who after the active therapy used a fixed combination of adapalene 0.1% / BPO 2.5% as maintenance treatment. Only 1 patient (2.9%) with moderate acne and 2 patients (5.8%) with severe acne had a relapse within 6 months of maintenance therapy. The absence of adverse events during the course of treatment was recorded, as well as high adherence of patients to the treatment. During the period of post-treatment observation (6 months after maintenance therapy), among the patients without exacerbations during maintenance therapy, a relapse occurred in 2 (7.1%) patients of group 1 (n = 28) and 2 (8.7%) patients of group 2 (n = 23). The obtained data indicates that maintenance therapy with Effezel® gel can extend the achieved effectiveness of the treatment and prevent the development of relapses.

scholarly journals Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Yongbing Pan ◽  
Jianhui Du ◽  
Jia Liu ◽  
Hai Wu ◽  
Fang Gui ◽  
...  
Keyword(s):  
Phage Display ◽  
Neutralizing Antibodies ◽  
Variable Region ◽  
Neutralizing Antibody ◽  
Chain Gene ◽  
Prophylactic Efficacy ◽  
Heavy Chains ◽  
Effective Interventions ◽  
Phage Display Libraries

AbstractAs the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to threaten public health worldwide, the development of effective interventions is urgently needed. Neutralizing antibodies (nAbs) have great potential for the prevention and treatment of SARS-CoV-2 infection. In this study, ten nAbs were isolated from two phage-display immune libraries constructed from the pooled PBMCs of eight COVID-19 convalescent patients. Eight of them, consisting of heavy chains encoded by the immunoglobulin heavy-chain gene-variable region (IGHV)3-66 or IGHV3-53 genes, recognized the same epitope on the receptor-binding domain (RBD), while the remaining two bound to different epitopes. Among the ten antibodies, 2B11 exhibited the highest affinity and neutralization potency against the original wild-type (WT) SARS-CoV-2 virus (KD = 4.76 nM for the S1 protein, IC50 = 6 ng/mL for pseudoviruses, and IC50 = 1 ng/mL for authentic viruses), and potent neutralizing ability against B.1.1.7 pseudoviruses. Furthermore, 1E10, targeting a distinct epitope on RBD, exhibited different neutralization efficiency against WT SARS-CoV-2 and its variants B.1.1.7, B.1.351, and P.1. The crystal structure of the 2B11–RBD complexes revealed that the epitope of 2B11 highly overlaps with the ACE2-binding site. The in vivo experiment of 2B11 using AdV5-hACE2-transduced mice showed encouraging therapeutic and prophylactic efficacy against SARS-CoV-2. Taken together, our results suggest that the highly potent SARS-CoV-2-neutralizing antibody, 2B11, could be used against the WT SARS-CoV-2 and B.1.1.7 variant, or in combination with a different epitope-targeted neutralizing antibody, such as 1E10, against SARS-CoV-2 variants.

Effect of Prophylactic Subcutaneous Scopolamine Butylbromide on Death Rattle in Patients at the End of Life

JAMA ◽  
2021 ◽  
Vol 326 (13) ◽  
pp. 1268
Author(s):  
Harriëtte J. van Esch ◽  
Lia van Zuylen ◽  
Eric C. T. Geijteman ◽  
Esther Oomen-de Hoop ◽  
Bregje A. A. Huisman ◽  
...  
Keyword(s):  
End Of Life ◽  
Scopolamine Butylbromide ◽  
Death Rattle

scholarly journals 1343. Prophylactic Dosing of Baloxavir Acid Eliminates Mortality in Mice Lethal Influenza A Virus Infection Model

2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S410-S411
Author(s):  
Shinya Shano ◽  
Keita Fukao ◽  
Takeshi Noshi ◽  
Kenji Sato ◽  
Masashi Sakuramoto ◽  
...  
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Virus Infection ◽  
Influenza A Virus ◽  
Influenza A ◽  
Lethal Dose ◽  
Body Weight Loss ◽  
Prophylactic Efficacy ◽  
Body Weights ◽  
Single Dosing

Abstract Background Baloxavir acid (BXA), an active form of orally available prodrug baloxavir marboxil (BXM, formerly S-033188), is a novel small molecule inhibitor of cap-dependent endonuclease (CEN) of influenza A and B virus, and was recently launched for the treatment of acute and uncomplicated influenza with single dosing of BXM (the trade name XOFLUZA™) in Japan in March 2018. Here, we evaluated the prophylactic efficacy of BXA in mice lethally infected with influenza A virus. Methods T1/2 of BXA in human is more than 10 times longer than that in mice. Therefore, suspension of BXA was subcutaneously administered at 0.8 or 1.6 mg/kg in mice to maintain the plasma concentration of BXA as seen in humans, and then mice were intranasally inoculated with a lethal dose of A/PR/8/34 strain at 48, 72, or 96 hours after the administration of BXA. Survival time and body weight change were then monitored through a 28-day period after virus infection. Mice were euthanized and regarded as dead if their body weights were lower than 70% of the initial body weights according to humane endpoints. Results Single dosing of BXA (1.6 mg/kg) completely eliminated mortality in mice, when the mice were administrated the drug at 48, 72, or 96 hours before virus infection (Figure 1). BXA treatment also significantly prevented body weight loss, consistent with the prolonged survival. Conclusion Prophylactic dosing of BXA exhibited significant protective efficacy against mortality and body weight loss in mice following a lethal infection with influenza A virus. The significant prophylactic efficacy observed in our mouse model suggests the potential utility of BXM for the prophylaxis of influenza in human. Disclosures S. Shano, Shionogi & Co., Ltd.: Employee, Salary. K. Fukao, Shionogi & Co., Ltd.: Employee, Salary. T. Noshi, Shionogi & Co., Ltd.: Employee, Salary. K. Sato, Shionogi & Co., Ltd.: Employee, Salary. M. Sakuramoto, Shionogi & Co., Ltd.: Employee, Salary. K. Baba, Shionogi TechnoAdvance Research & Co., Ltd.: Employee, Salary. T. Shishido, Shionogi & Co., Ltd.: Employee, Salary. A. Naito, Shionogi & Co., Ltd.: Employee, Salary.

Evaluation of the Prophylactic Efficacy of Amitriptyline and Citalopram, Alone or in Combination, in Patients with Comorbidity of Depression, Migraine, and Tension-Type Headache

2004 ◽  
Vol 50 (4) ◽  
pp. 322-328 ◽  
Author(s):  
Liborio Rampello ◽  
Alessandro Alvano ◽  
Santina Chiechio ◽  
Mariano Malaguarnera ◽  
Rocco Raffaele ◽  
...  
Keyword(s):  
Tension Type Headache ◽  
Prophylactic Efficacy ◽  
Type Headache

scholarly journals Prophylaxis of Plasmodium falciparumInfection in a Human Challenge Model with WR 238605, a New 8-Aminoquinoline Antimalarial

1998 ◽  
Vol 42 (5) ◽  
pp. 1293-1294 ◽  
Author(s):  
Ralf P. Brueckner ◽  
Trinka Coster ◽  
David L. Wesche ◽  
Moshe Shmuklarsky ◽  
Brian G. Schuster
Keyword(s):  
Plasmodium Falciparum ◽  
Oral Dose ◽  
Single Oral Dose ◽  
Prophylactic Efficacy ◽  
Drug Concentrations ◽  
Prophylactic Drug

ABSTRACT The prophylactic efficacy of WR 238605, a primaquine analog, was studied with a human Plasmodium falciparum challenge model. A single oral dose of 600 mg, administered 1 day prior to challenge, successfully protected three of four subjects. The fourth subject developed mild, oligosymptomatic malaria on day 31, with drug concentrations one-half of those in the protected individuals. WR 238605 appears to be a promising prophylactic drug for P. falciparum malaria.

Sign in / Sign up

Export Citation Format

Share Document